Ultragenyx Pharmaceutical Inc.
Symbol: RARE
NASDAQ
43.01
USDTrhová cena dnes
-5.9104
Pomer P/E
0.0654
Pomer PEG
3.54B
MRK Cap
- 0.00%
Výnos DIV
Ultragenyx Pharmaceutical Inc. (RARE) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2271.64 | 777.1 | 896.7 | 999.1 | |||||||||||||
balance-sheet.row.short-term-investments | 1482.9 | 363.6 | 614.8 | 432.6 | |||||||||||||
balance-sheet.row.net-receivables | 323.63 | 73.4 | 40.4 | 28.4 | |||||||||||||
balance-sheet.row.inventory | 129.93 | 34 | 26.8 | 16.2 | |||||||||||||
balance-sheet.row.other-current-assets | -638.48 | -777.1 | 68.9 | -187.2 | |||||||||||||
balance-sheet.row.total-current-assets | 2554.45 | 732.2 | 883.9 | 856.6 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 1207.13 | 290.6 | 285.7 | 176.2 | |||||||||||||
balance-sheet.row.goodwill | 177.62 | 44.4 | 44.4 | 44.4 | |||||||||||||
balance-sheet.row.intangible-assets | 646.86 | 166.3 | 160.1 | 130.8 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 824.48 | 210.7 | 204.5 | 175.2 | |||||||||||||
balance-sheet.row.long-term-investments | 436.17 | 199.9 | 154.5 | 293.9 | |||||||||||||
balance-sheet.row.tax-assets | 80.98 | 6 | 6.1 | 8.9 | |||||||||||||
balance-sheet.row.other-non-current-assets | 244.34 | 51.7 | 10.7 | 11.6 | |||||||||||||
balance-sheet.row.total-non-current-assets | 2793.09 | 758.8 | 661.5 | 665.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.account-payables | 158.56 | 42.1 | 43.3 | 17.1 | |||||||||||||
balance-sheet.row.short-term-debt | 91.02 | 12.6 | 11.8 | 11.1 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 928.7 | 30.6 | 19.8 | 30.9 | |||||||||||||
Deferred Revenue Non Current | 1736.75 | 862.3 | 0 | 1.5 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 123.45 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 410.65 | 29.2 | 204.7 | 145.6 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3746.75 | 935.2 | 931.7 | 418.5 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 108.94 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.total-liab | 4771.12 | 1215.6 | 1193 | 599.8 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.31 | 0.1 | 0.1 | 0.1 | |||||||||||||
balance-sheet.row.retained-earnings | -13315.3 | -3387.7 | -2781 | -2073.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -1.79 | 0.6 | -6.6 | -1.4 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 13893.21 | 3662.3 | 3140 | 2997.5 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5347.54 | - | - | - | |||||||||||||
Total Investments | 1852.69 | 563.5 | 620.3 | 726.5 | |||||||||||||
balance-sheet.row.total-debt | 1013.14 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.net-debt | 506.37 | -170.4 | -101.4 | -265.6 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -613.35 | -606.6 | -707.4 | -454 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 29.61 | 26 | 18.2 | 13.2 | |||||||||||||
cash-flows.row.deferred-income-tax | -143.91 | -1.6 | -1.6 | 48.7 | |||||||||||||
cash-flows.row.stock-based-compensation | 140.2 | 135.2 | 130.4 | 105 | |||||||||||||
cash-flows.row.change-in-working-capital | -32.76 | -15.1 | 60.2 | -63.2 | |||||||||||||
cash-flows.row.account-receivables | -45.18 | -22.8 | -12.1 | -5.4 | |||||||||||||
cash-flows.row.inventory | -9.2 | -6.9 | -9.7 | -3.1 | |||||||||||||
cash-flows.row.account-payables | -0.41 | 2.4 | 87.4 | 2.8 | |||||||||||||
cash-flows.row.other-working-capital | 22.04 | 12.2 | -5.4 | -57.5 | |||||||||||||
cash-flows.row.other-non-cash-items | 228.72 | -12.7 | 119.8 | 11.7 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -508.67 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -2.5 | -75 | 0 | |||||||||||||
cash-flows.row.purchases-of-investments | -486.29 | -526.4 | -614.7 | -1012.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 675.52 | 746.2 | 545.1 | 890.9 | |||||||||||||
cash-flows.row.other-investing-activites | -0.66 | -2.5 | -0.8 | -0.9 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 151.13 | 168 | -291.7 | -195.4 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -490.9 | 0 | |||||||||||||
cash-flows.row.common-stock-issued | 354.26 | 379.8 | 10.8 | 78.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | -0.06 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 34.55 | 8.4 | 981.3 | 39.6 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 388.81 | 388.1 | 501.2 | 118.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.43 | 0.5 | -1.1 | -1.2 | |||||||||||||
cash-flows.row.net-change-in-cash | 34.89 | 85.6 | -172 | -416.7 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 524.23 | 219.4 | 137.6 | 309.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 489.34 | 133.8 | 309.6 | 726.3 | |||||||||||||
cash-flows.row.operating-cash-flow | -508.67 | -474.8 | -380.5 | -338.7 | |||||||||||||
cash-flows.row.capital-expenditure | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.free-cash-flow | -543.61 | -521.6 | -526.6 | -411.8 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 442.59 | 434.2 | 363.3 | 351.4 | |||||||||||||
income-statement-row.row.cost-of-revenue | 59.33 | 45.2 | 28.3 | 16 | |||||||||||||
income-statement-row.row.gross-profit | 383.26 | 389 | 335 | 335.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 652.39 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 5.24 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.operating-expenses | 963.71 | 958.2 | 983.9 | 717.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1023.04 | 1003.5 | 1012.2 | 733.1 | |||||||||||||
income-statement-row.row.interest-income | 29.22 | 26.7 | 11.1 | 1.9 | |||||||||||||
income-statement-row.row.interest-expense | 34.52 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 5.24 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.interest-expense | 34.52 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 27.61 | 26 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.ebitda-caps | -538.27 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -580.45 | -569.2 | -648.9 | -381.7 | |||||||||||||
income-statement-row.row.income-before-tax | -615.22 | -608.5 | -701.7 | -453 | |||||||||||||
income-statement-row.row.income-tax-expense | -1.86 | -1.8 | 5.7 | 1 | |||||||||||||
income-statement-row.row.net-income | -613.35 | -606.6 | -707.4 | -454 |
Často kladené otázky
Čo je Ultragenyx Pharmaceutical Inc. (RARE) celkové aktíva?
Ultragenyx Pharmaceutical Inc. (RARE) celkové aktíva sú 1491013000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 236225000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.866.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -6.450.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -1.386.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -1.311.
Aká je Ultragenyx Pharmaceutical Inc. (RARE) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -606639000.000.
Aký je celkový dlh firmy?
Celkový dlh je 43169000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 958248000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 118554000.000.